Side effects of bone-targeted therapies in advanced breast cancer. - Wikidata - awgldk - TriplyDB

Side effects of bone-targeted therapies in advanced breast cancer.

Side effects of bone-targeted therapies in advanced breast cancer.

http://www.wikidata.org/entity/Q35066955

about

Bone-Targeted Therapy Potential Effects of Phytoestrogen Genistein in Modulating Acute Methotrexate Chemotherapy-Induced Osteoclastogenesis and Bone Damage in Rats.Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial.Human serum albumin-mediated apoptin delivery suppresses breast cancer cell growth in vitro and in vivo Hypercalcaemia and hypocalcaemia: finding the balance.Nephrotoxicity of anticancer treatment.Hypericin targets osteoclast and prevents breast cancer-induced bone metastasis via NFATc1 signaling pathway.Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion

P2860

Q28081294-102CB0EC-F24C-4C75-A581-84A14B2CF8CB Q36088558-D91C1AA8-295A-429E-A965-7F10C770E114 Q37094993-2A69C97F-D3D1-4955-AD29-8981B5405F82 Q37701064-8ECF3466-779A-4E08-A640-2C30605751E6 Q37736066-DECDEC41-8D44-40F3-94A6-2E38A56498DF Q39198933-C8CD502F-F9A9-43DA-BAC2-55F6B0A65F73 Q49299129-ED81DD87-1E50-4D01-8297-E4FA7E2D5417 Q57105768-7B1DE8A1-40AB-4FD6-8EA6-397999BF953D

P2860

Side effects of bone-targeted therapies in advanced breast cancer.

http://www.wikidata.org/entity/Q35066955

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Side effects of bone-targeted therapies in advanced breast cancer.

@ast

Side effects of bone-targeted therapies in advanced breast cancer.

@en

type

label

Side effects of bone-targeted therapies in advanced breast cancer.

@ast

Side effects of bone-targeted therapies in advanced breast cancer.

@en

prefLabel

Side effects of bone-targeted therapies in advanced breast cancer.

@ast

Side effects of bone-targeted therapies in advanced breast cancer.

@en

P1433

Q35066955-6FA8D2CE-131D-40E0-BD87-B10914636D0F

P1476

Q35066955-5BFE21A8-B42A-4A3E-8E06-94006652BAC6

P2093

Q35066955-414D5C4E-54BC-4CB4-827A-06CE16563B8E

Q35066955-790431C7-0C6F-4332-96F8-4C140737FE3A

P2860

Q35066955-000BA288-2DAA-4E45-A082-F4048A725D28

Q35066955-098C0F23-5C6D-4A1D-8445-627F3D0F2B7B

Q35066955-10869789-8EC7-4917-BE68-DED703E98008

Q35066955-1691315A-2530-45BF-957A-FD0548B319BF

Q35066955-1FD855EE-D5F5-4F86-8BE6-6E1F87FD39DE

Q35066955-2B11B2AC-B6D7-469E-BFEE-EDA0187748A2

Q35066955-3210A189-DA00-4248-A3E2-819A64E6726E

Q35066955-35879A7B-1D0F-40CE-87C2-F840A621F7DB

Q35066955-37F4D4A0-E593-43E8-BB07-5A645246AC9B

Q35066955-38A0F977-31A3-46F9-B2D6-3A82828B4448

P304

Q35066955-670C85D0-D77D-4FD5-8062-04D6380BD2A5

P31

Q35066955-2C4BE162-95A7-4289-B643-3378DA035368

P356

Q35066955-1B27D035-0074-4091-9EA1-BAC6E58612CA

P433

Q35066955-3B58B5CF-3CF4-4453-95D5-5E47BB23FA60

P478

Q35066955-DA07874F-26A0-4B1C-B5E7-AF63B83823BF

P577

Q35066955-BDCA3DAE-16BE-4455-8339-55907DDF9529

P698

Q35066955-B7F366A5-17C1-4652-A131-7186BEC602CC

P932

Q35066955-C67A02EC-5055-4A35-B32E-2961C4FAC7F4

P356

P1433

P1476

Side effects of bone-targeted therapies in advanced breast cancer.

@en

P2093

Christoph Domschke

http://www.w3.org/2001/XMLSchema#string

Florian Schuetz

http://www.w3.org/2001/XMLSchema#string

P2860

Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications

Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials.

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis.

The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

Clinical features of metastatic bone disease and risk of skeletal morbidity.

American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer.

P304

332-336

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000368844

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25759613

http://www.w3.org/2001/XMLSchema#string

P932

4322699

http://www.w3.org/2001/XMLSchema#string